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Abstract
Introduction: Cationic antimicrobial peptides (CAPs) defend against microbial pathogens; however, certain CAPs
also exhibit anticancer activity. The purpose of this investigation was to determine the effect of the pleurocidin-
family CAPs, NRC-03 and NRC-07, on breast cancer cells.
Methods: MTT (3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide) and acid phosphatase cell-viability
assays were used to assess NRC-03- and NRC-07-mediated killing of breast carcinoma cells. Erythrocyte lysis was
determined with hemolysis assay. NRC-03 and NRC-07 binding to breast cancer cells and normal fibroblasts was
assessed with fluorescence microscopy by using biotinylated-NRC-03 and -NRC-07. Lactate dehydrogenase-release
assays and scanning electron microscopy were used to evaluate the effect of NRC-03 and NRC-07 on the cell
membrane. Flow-cytometric analysis of 3,3’-dihexyloxacarbocyanine iodide- and dihydroethidium-stained breast
cancer cells was used to evaluate the effects of NRC-03 and NRC-07 on mitochondrial membrane integrity and
reactive oxygen species (ROS) production, respectively. Tumoricidal activity of NRC-03 and NRC-07 was evaluated in
NOD SCID mice bearing breast cancer xenografts.
Results: NRC-03 and NRC-07 killed breast cancer cells, including drug-resistant variants, and human mammary
epithelial cells but showed little or no lysis of human dermal fibroblasts, umbilical vein endothelial cells, or
erythrocytes. Sublethal doses of NRC-03 and, to a lesser extent, NRC-07 significantly reduced the median effective
concentration (EC50) of cisplatin for breast cancer cells. NRC-03 and NRC-07 bound to breast cancer cells but not
fibroblasts, suggesting that killing required peptide binding to target cells. NRC-03- and NRC-07-mediated killing of
breast cancer cells correlated with expression of several different anionic cell-surface molecules, suggesting that
NRC-03 and NRC-07 bind to a variety of negatively-charged cell-surface molecules. NRC-03 and NRC-07 also caused
significant and irreversible cell-membrane damage in breast cancer cells but not in fibroblasts. NRC-03- and NRC-
07-mediated cell death involved, but did not require, mitochondrial membrane damage and ROS production.
Importantly, intratumoral administration of NRC-03 and NRC-07 killed breast cancer cells grown as xenografts in
NOD SCID mice.
Conclusions: These findings warrant the development of stable and targeted forms of NRC-03 and/or NRC-07 that
might be used alone or in combination with conventional chemotherapeutic drugs for the treatment of breast
cancer.
* Correspondence: d.w.hoskin@dal.ca
1Department of Microbiology & Immunology, Dalhousie University, 5850
College St., Halifax, B3H 4R2, Canada
Full list of author information is available at the end of the article
Hilchie et al. Breast Cancer Research 2011, 13:R102
http://breast-cancer-research.com/content/13/5/R102
© 2011 Hoskin et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Introduction
Despite the decline in the incidence and mortality rates
of breast cancer from 1990 to 2005, an estimated
192,370 women were expected to be diagnosed with
breast cancer in 2009, and 40,170 women were expected
to die of the disease, representing nearly 15% of all can-
cer-related deaths in American women [1]. Although
the treatment of breast cancer varies significantly
between patients, treatment options typically include
surgery, radiotherapy, chemotherapy, endocrine thera-
pies, and/or administration of trastuzumab [2]. Conven-
tional chemotherapeutic drugs indiscriminately target
rapidly dividing cells. Consequently, these drugs fail to
kill slow-growing or dormant cancer cells and kill
healthy cells that are also rapidly growing, which can
lead to adverse side-effects without a reduction in
tumor burden [3,4]. The development of multidrug-
resistant cancer cells that overexpress drug-efflux
pumps such as P-glycoprotein further reduce the effec-
tiveness of conventional chemotherapeutic agents [5].
Furthermore, endocrine-based therapies can lead to the
development of secondary malignancies [6]. These
shortcomings have led to the development of novel
drugs such as trastuzumab (Herceptin), which selectively
kill breast cancer cells that express the HER2/neu recep-
tor [7]. However, resistance to trastuzumab caused by
altered signal-transduction pathways and decreased
interactions between trastuzumab and HER2/neu has
already been documented [8]. The need, therefore, per-
sists for a new class of anticancer drugs with the ability
to kill cancer cells selectively, regardless of their prolif-
erative capacity, reliance on specific signal-transduction
pathways, or the presence of multidrug-resistance pro-
teins. In this regard, certain cationic antimicrobial pep-
tides (CAPs) represent a promising supplement or
alternative to current anticancer agents.
CAPs are small peptides (typically consisting of < 50
amino acid residues) that function as an important com-
ponent of the innate immune system [9]. CAPs are pre-
dominantly composed of basic and hydrophobic amino
acids and are classified as a-helical, b-sheet, loop, or
extended peptides based on the secondary structure that
they adopt when in contact with biologic membranes
[10]. Compared with normal cells, which have zwitterio-
nic lipids in their membranes and are therefore neutral in
charge, the outer-membrane leaflet of cancer cells carries
a net negative charge because of a greater abundance of
phosphatidylserine residues, O-sialoglycoproteins, and
heparan sulfate proteoglycans [9,11]. Consequently, cer-
tain CAPs have been shown to have a 10-fold greater
binding affinity for neoplastic cells in comparison with
normal cells, making these CAPs selectively cytotoxic for
cancer cells [12]. On binding to the cell, the hydrophobic
amino acid side chains of the CAP insert into the
hydrophobic core of the membrane, granting the CAP
access to the cytosol, and/or leading to cytolysis.
Increased transmembrane potential, surface area, and
membrane fluidity, all of which are associated with neo-
plastic cells, may also contribute to the selective cytotoxic
activity of certain CAPs [9]. Although many CAPs are
cytolytic, others, such as bovine lactoferricin, induce
apoptosis in human cancer cell lines through a mechan-
ism that involves reactive oxygen species (ROS) produc-
tion and mitochondrial membrane destabilization [13].
Certain CAPs kill a wide range of human cancer cells,
including multidrug-resistant variants, and show activity
against primary tumors and metastatic disease without
causing undue harm to vital organs [9,14-18]. Further-
more, because the charge of the cell and not its growth
rate determines susceptibility to CAP-mediated cytotoxi-
city, CAPs are also predicted to target slow-growing or
dormant cancer cells. Moreover, resistance of cancer
cells to cytolytic CAPs is unlikely, because CAPs are
attracted to many negatively-charged surface molecules
rather than interacting with a unique receptor; to our
knowledge, cancer cell resistance to lytic CAPs has
never been documented. In addition, intratumoral
administration of lytic peptides has been reported to
cause T cell-dependent tumor regression in immune-
competent mice and protect the animal from tumor
rechallenge [19]. Finally, certain CAPs enhance the cyto-
toxic activity of traditional anticancer drugs that require
access to the cytoplasm to exert their cytotoxic effect
[20,21]. Taken together, these findings suggest that
CAPs with anticancer activity may be a valuable addi-
tion to the medical oncologist’s armamentarium.
Fish are heavily dependent on their innate immune
system for defense against microbial pathogens and
therefore harbor a plethora of novel CAPs with potential
anticancer activities. In 2003, 20 pleurocidin-like CAPs
(NRC-01 to -20) were identified in various Atlantic
flounder species and screened for antimicrobial activity
[22]. Our initial screen of a subset of these CAPs
revealed that NRC-03 and NRC-07 possess anticancer
activity. The amino acid sequence of NRC-03 suggests
that when in contact with biologic membranes, NRC-03
contains an unstructured cationic amino terminus fol-
lowed by an a-helical segment that is kinked near the
carboxy-terminus because of the presence of two glycine
residues. The amino acid sequence of NRC-07 suggests
the formation of a complete a-helix under similar con-
ditions. It is noteworthy that other a-helical CAPs, such
as melittin, exhibit potent hemolytic activity [23].
The purpose of this investigation was to determine
whether NRC-03 and NRC-07 selectively kill breast can-
cer cells, including drug-resistant breast cancer cells; to
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cytotoxic activity of traditional chemotherapeutic drugs;
to determine the mechanism of action of NRC-03 and
NRC-07; and to study in vivo activity of NRC-03 and
NRC-07 in a xenograft tumor model. Both NRC-03 and
NRC-07 were found to kill breast carcinoma cells,
including drug-resistant and slow-growing breast cancer
cells. NRC-03 and NRC-07 also reduced the EC50 of cis-
platin, suggesting their possible use in combination ther-
apy. NRC-03- and NRC-07-mediated cell death
correlated with peptide binding to anionic surface mole-
cules. Importantly, NRC-03 and NRC-07 killed breast
cancer cells that were grown as xenografts in immune-
deficient mice. This is the first study to evaluate pleuro-
cidin family CAPs in terms of their cytotoxicity for
breast cancer cells, their mechanism of action, and in
vivo antitumor activity.
Materials and methods
Cell culture and conditions
MDA-MB-231 breast cancer cells were obtained from
D r .S .D r o v e r( M e m o r i a lU n i v e r s i t yo fN e w f o u n d l a n d ,
St. John’s, NL, Canada). MDA-MB-468, T47-D, SKBR3,
MCF7, and paclitaxel-resistant MCF7 (MCF7-TX400)
breast cancer cells were obtained from Drs. P. Lee, J.
Blay, G. Dellaire, and K. Goralski, respectively (Dalhou-
sie University, Halifax, NS, Canada). 4T1 mouse mam-
mary carcinoma cells were obtained from Dr. D.
Waisman (Dalhousie University). Human erythrocytes
were obtained from Dr. R. Duncan (Dalhousie Univer-
sity). L cells (immortalized mouse fibroblasts), gro2C
cells (heparan sulfate proteoglycan-deficient L cells), and
sog9 cells (heparan and chondroitin sulfate proteogly-
can-deficient L cells) [24,25], as well as ATG5
+/+ and
ATG5
-/- mouse embryo fibroblasts [26] were obtained
from Dr. C. MacCormick (Dalhousie University). All
cells were maintained at 37°C in a 5% or 10% CO2
humidified atmosphere in RPMI 1640 or DMEM med-
ium (Sigma-Aldrich Canada, Oakville, ON, Canada),
respectively. All media were supplemented with 100 U/
ml penicillin, 100 μg/ml streptomycin, 2 mM L-gluta-
mine, 5 mM HEPES (pH 7.4), and 10% heat-inactivated
fetal bovine serum (FBS) (Invitrogen, Burlington, ON,
Canada). Stock flasks were passaged as required to
maintain optimal cell growth and were routinely con-
firmed to be free from Mycoplasma contamination;
however, none of the cell lines has been authenticated.
Primary cultures of human umbilical vein endothelial
cells (HUVECs), human mammary epithelial cells
(HMECs), and human dermal fibroblasts were obtained
from Lonza Inc. and maintained in Clonetics EGM-2,
MEGM, and FGM-2, respectively, at 37°C in a 5% CO2
humidified atmosphere for a maximum of six passages.
Reagents
NRC-03 (amino acid sequence: GRRKRKWLRRIGKGV-
KIIGGAALDHL-NH2) and NRC-07 (RWGKWFKKATH
VGKHVGKAALTAYL-NH2) were synthesized by Dalton
Pharma Services (Toronto, ON, Canada) or American
Peptide Company (Sunnyvale, CA, USA). NRC-13
(GWRTLLKKAEVKTVGKLALKHYL-NH2), biotiny-
lated-NRC-03, and biotinylated-NRC-07 were synthe-
sized by Dalton Pharma Services. Peptides were
biotinylated at the N-terminus and were > 95% pure.
Lyophilized peptides were reconstituted in serum-free
DMEM. All experiments were conducted in medium
containing 2.5% FBS to limit peptide degradation by
serum proteases. Reduced glutathione (GSH), 3-(4,5-
dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide
(MTT), paclitaxel, cisplatin, triethylammonium bicarbo-
nate buffer, trifluoroacetic acid, heparan sulfate sodium
salt, chondroitin sulfate sodium salt, phosphatase assay
substrate, and crystal violet were purchased from Sigma-
Aldrich (Oakville, ON, Canada). Sequencing-grade tryp-
sin was obtained from Promega (Madison, WI, USA).
Matrix-assisted laser desorption ionization-time of flight
(MALDI-TOF) matrix solution was from Agilent Tech-
nologies (Palo Alto, CA, USA). Avidin-conjugated horse-
radish peroxidase (HRP) was purchased from BD
Biosciences (San Jose, CA, USA). Hank’s balanced salt
solution (HBSS) was obtainedf r o mI n v i t r o g e n .B o c - D -
FMK (pan-caspase inhibitor) was purchased from EMD
Biosciences (San Diego, CA, USA). Streptavidin-conju-
gated Texas Red fluorophore was purchased from Jack-
son Immunoresearch Laboratories (West Grove, PA,
USA). O-sialoglycoprotein endopeptidase (OSGE) was
obtained from Cedarlane Laboratories (Hornby, ON,
Canada). Dihydroethidium (DHE), 3,3’-dihexyloxacarbo-
cyanine iodide (DiOC6), and Alexa Fluor 488-conjugated
phalloidin were purchased from Molecular Probes
(Eugene, OR, USA). Mouse anti-cytochrome c monoclo-
nal antibody (mAb) was from Upstate Biotechnology
(Charlottesville, VA, USA), and mouse anti-mitochon-
drial Hsp70 mAb was obtained from Affinity BioReagents
(Golden, CO, USA). HRP-conjugated goat anti-mouse
IgG was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Fluorescein isothiocyanate
(FITC)-conjugated anti-mouse IgG was from eBioscience
(San Diego, CA, USA).
Animals
Adult (6- to 7-week old) female NOD SCID mice pur-
chased from Charles River Canada (Lasalle, QC, Canada)
were housed in the Carleton Animal Care Facility and
were maintained on a diet of sterilized rodent chow and
water ad libitum. Animal use was approved by the Dal-
housie University Committee on Laboratory Animals
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mal Care guidelines.
MTT assay
Breast cancer cell viability was determined by using the
M T Ta s s a y .I nb r i e f ,2×1 0
4 breast cancer cells were
plated, in quadruplicate, in 96-well flat-bottom tissue-
culture plates (Sarstedt, St. Leonard, QC, Canada). After
24-hour culture to promote cellular adhesion, cells were
cultured under the indicated conditions for an addi-
t i o n a l4o r2 4h o u r s .M T T( 1 0 0μg) was added to the
c u l t u r ef o rt h ef i n a l2h o u r s ,a n dt h ef o r m a z a nc r y s t a l s
were subsequently solubilized in DMSO (100 μl/well).
Absorbance (490 nm) was measured by using a Bio-Tek
microplate reader (Bio-Tek Instruments, Winooski, VT,
USA). Percentage cytotoxicity was calculated by the for-
mula [1-E/C] × 100, where E and C denote the optical
density of peptide- and medium-treated cells,
respectively.
Acid phosphatase assay
The acid phosphatase assay was used instead of the
MTT assay to compare NRC-03 and NRC-07 killing of
paclitaxel-resistant MCF7-TX400 to wild-type MCF7
cells because drug-efflux pumps interfere with the
reduction of MTT [27]. In brief, cells cultured as
described for the MTT assay were thoroughly washed
with PBS and incubated in 0.1 ml assay buffer (0.1 M
sodium acetate, 0.1% Triton X-100 (vol/vol), 4 mg/ml
phosphatase substrate) for 90 minutes. The reaction was
stopped by the addition of 10 μl 1N NaOH. The optical
density (405 nm) was measured, and the percentage
cytotoxicity was calculated as described for the MTT
assay.
Hemolysis assay
The hemolytic activity of NRC-03 and NRC-07 was
determined by culturing human erythrocytes (5% (vol/
vol) in PBS) in the presence or absence of the indicated
concentrations of NRC-03 and NRC-07 for 8 hours in
96-well round-bottomed tissue-culture plates (Sarstedt).
Maximum hemolysis was achieved by combining ery-
throcytes with an equal volume of water. Erythrocytes
were then pelleted (1,400 g), and supernatants were
transferred to 96-well flat-bottomed tissue-culture plates
for analysis. Absorbance (490 nm) was measured, and
the percentage hemolysis was calculated by using the
equation ((E/S)/(M/S)) × 100, where E and S and M
denote experimental, spontaneous, and maximal hemo-
lysis, respectively.
Peptide-binding assay
MDA-MB-231 cells and human dermal fibroblasts (8 ×
10
5 cells) plated in six-well flat-bottom tissue-culture
plates containing sterile coverslips were incubated for 24
hours to promote cell adhesion to the coverslips. Adher-
ent cells were cultured for 10 minutes in the presence
or absence of 50 μM biotinylated-NRC-03 or -NRC-07.
Cells on the coverslips were then fixed with paraformal-
dehyde (4% (wt/vol) in PBS), washed extensively with
PBS, and exposed to Texas Red-conjugated streptavidin
(1:1,000) for 45 minutes. After extensive washing with
PBS, the coverslips were mounted on slides with Dako
fluorescent mounting medium (Dako Canada, Missis-
sauga, ON, Canada). Cells were visualized with phase
and fluorescent microscopy at ×400 magnification.
Fluorescence per cell was determined by using NIS-Ele-
ments software (Nikon Canada, Mississauga, ON,
Canada).
Solid-phase heparan sulfate- and chondroitin sulfate-
binding assays
Binding of biotinylated-NRC-03 and biotinylated-NRC-
07 to plastic-immobilized heparan sulfate or chondroitin
sulfate was determined by using a modification of a pre-
viously described protocol [28]. In brief, 10 μg/ml
heparan sulfate or chondroitan sulfate in 15 mM
Na2CO3 and 35 mM NaHCO3 buffer (pH 9.2) were
incubated overnight in EIA plates at 4°C. Plates were
washed with PBS, blocked for 2 hours with 10% FBS,
washed again with PBS, and incubated for 2 hours at
23°C in the presence or absence of 50 μM biotinylated-
NRC-03 or biotinylated-NRC-07. Plates were then
washed with PBS, incubated with avidin-HRP (1:1,000 in
PBS) for 1 h, washed with PBS, and incubated with
TMB substrate solution. The reaction was stopped by
the addition of 0.3 M H2SO4.P e p t i d eb i n d i n gt o
heparan sulfate or chondroitin sulfate was determined
by measuring absorbance at 450 nm.
Scanning electron microscopy
MDA-MB-231 cells and human dermal fibroblasts (2 ×
10
5 cells) were plated in 24-well flat-bottom tissue-cul-
ture plates (Sarstedt) containing sterile circular cover-
slips and incubated overnight to promote cellular
adhesion. Cells on coverslips were cultured in the pre-
sence or absence of 25 or 50 μM NRC-03, NRC-07, or
NRC-13 for 10 or 30 minutes. The cells were washed
with 0.1 M sodium cacodylate and fixed with glutaralde-
hyde (2.5% (vol/vol) in sodium cacodylate) for 2 hours.
The cells were washed again, fixed with osmium tetrox-
ide (1% (wt/vol) in sodium cacodylate) for 30 minutes,
washed again, and dehydrated in increasing concentra-
tions of ethanol until a final concentration of 100%
ethanol was achieved. The samples were subsequently
dried to their critical point by using a Polaron E3000
Critical Point Dryer (Quorum Technologies, Guelph,
ON, Canada), mounted onto stubs, and coated with
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(Quorum Technologies). The cells were then viewed at
the Institute for Research in Materials (Dalhousie Uni-
versity) on a Hitachi S4700 scanning electron micro-
scope (Hitachi High Technologies, Rexdale, ON,
Canada) at ×7,000 and ×40,000 magnification.
Lactate dehydrogenase (LDH)-release assay
The LDH-release assay (CytoTox 96 Non-Radioactive
Cytotoxicity Assay; Promega Corporation, Madison, WI,
USA) was used per the manufacturer’si n s t r u c t i o n st o
quantify cytolysis and to validate cell-viability measure-
ments obtained with MTT assay. Complete cytolysis was
achieved by repeated freeze/thaw cycles. Absorbance
(490 nm) was used to calculate cytolysis by using the
equation ((E/S)/(M/S)) × 100, where E and S and M
denote experimental, spontaneous, and maximal release
of LDH, respectively.
Measurement of mitochondrial transmembrane potential
and ROS production
Flow-cytometric analysis of MDA-MB-231 cells stained
with DiOC6 or DHE was used to measure changes in
mitochondrial transmembrane potential and ROS pro-
duction, respectively. In brief, 5 × 10
5 MDA-MB-231
cells were cultured in the presence or absence of 50 μM
NRC-03 or NRC-07 for 30 minutes, and then exposed
to DHE (2.5 μM)o rD i O C 6 (40 nM)1 5m i n u t e sb e f o r e
analysis with a FACS Calibur flow cytometer (BD Bios-
ciences, San Jose, CA, USA).
Mitochondria isolation and Western blotting
Mitochondria were isolated from MDA-MB-231 cells, as
previously described [29], and treated with or without 50
μM NRC-03 or NRC-07 for 10 minutes. Mitochondria-
free supernatant (cytosolic fraction) was then collected
by centrifugation at 12,000 g for 10 minutes, and the
mitochondria pellet was lysed with ice-cold lysis buffer
(50 mM Tris (pH 7.5), 150 mM NaCl, 50 mM Na2HPO4,
0.25% sodium deoxycholate (wt/vol), 0.1% Nonidet P-40
(vol/vol), 100 μM Na3VO4,1 0m M NaF, 5 mM EDTA,
and 5 mM EGTA) containing freshly added protease
inhibitors (final concentration: 1 mM phenylmethylsulfo-
nyl fluoride, 10 μg/ml aprotinin, 5 μg/ml leupeptin, 10
μM phenylarsine oxide, 1 mM dithiothreitol, and 5 μg/ml
pepstatin). Supernatants containing proteins released by
lysed mitochondria were collected by centrifugation at
12,000 g. Protein concentrations in cytosolic and mito-
chondrial fractions were determined with the Bradford
assay (Bio-Rad Laboratories), and equal amounts of pro-
tein (5 μg) were resolved on a 12% SDS-polyacrylamide
gel. Proteins were transferred to nitrocellulose mem-
branes, and the resulting blots were blocked for 1 hour in
TBS-Tween (0.25 M Tris (pH 7.5), 150 mM NaCl, 0.2%
Tween-20 (vol/vol)) containing 5% powdered skim milk
( w t / v o l )a n dp r o b e do v e r n i g ht with the desired primary
antibody (1:500). Blots were then washed extensively
with TBS-Tween and probed for 1 hour with HRP-conju-
gated goat anti-mouse IgG (1:1,000). After additional
washes, cytochrome c or mitochondrial Hsp70 was visua-
lized by using an enhanced chemiluminescence detection
system (Bio-Rad Laboratories).
Confocal microscopy
NRC-03 and NRC-07 subcellular localization was deter-
mined by confocal microscopy. In brief, MDA-MB-231
cells (4 × 10
5) were seeded in six-well flat-bottom tis-
sue-culture plates containing sterile coverslips and were
incubated overnight to promote cellular adherence.
Cells were then cultured in the presence or absence of
biotinylated-NRC-03 or biotinylated-NRC-07 for 30 sec-
onds, washed with PBS, fixed with 4% paraformalde-
hyde, and washed again with PBS. Cells were then
stained with 5 U Alexa Fluor 488 phalloidin (in 0.1%
Triton-X 100), TO-PRO-3 iodide (1:1,000 in PBS), or
anti-mitochondrial Hsp70 mAb (1:50 in PBS) and FITC-
conjugated anti-mouse IgG (1:500 in PBS) for 20 min-
utes, 10 minutes, and 1 hour, respectively. Stained cells
were washed with PBS, incubated in Texas Red-conju-
gated streptavidin (1.54 μg/ml in PBS) for 45 minutes,
washed with PBS, dried, and mounted onto slides by
using Dako fluorescent mounting medium. Images
(×1,000) were acquired by using an LSM-510 META
laser scanning confocal microscope (Carl Zeiss Canada
Ltd., Toronto, ON, Canada).
TUNEL staining
DNA fragmentation was detected by using the TUNEL
assay according to the manufacturer’s instructions
(Roche Diagnostics, Laval, QC, Canada). In brief, MDA-
MB-231 breast cancer cells (4 × 10
5) were seeded into
six-well flat-bottom tissue-culture plates containing ster-
ile coverslips, and were incubated overnight to promote
cellular adherence. Cells were incubated in the presence
or absence of NRC-03 or NRC-07 for 30 minutes,
washed with PBS, fixed with 4% paraformaldehyde,
washed again with PBS, and incubated at 4°C for 2 min-
utes in permeabilization solution (0.1% Triton X-100
(vol/vol) in 0.1% sodium citrate (wt/vol)). Cells were
then washed with PBS, dried, and stained with TUNEL
reaction mixture for 1 hour at 37°C. Stained samples
were washed with PBS, dried, mounted on slides by
using Dako fluorescent mounting medium, and visua-
lized under visible and UV light (×400).
Mass spectroscopy
NRC-03 and NRC-07 reconstituted in 50 mM TEAB
buffer were incubated in the presence or absence of
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0.1% TFA, and diluted 1:1 in Matrix Solution. Samples
(500 ng) were spotted on a MALDI plate, dried, and
analyzed with a MALDI-TOF mass spectrometer
(Waters Corp., Milford, MA, USA).
Breast cancer xenografts
NOD SCID mice were engrafted with 5 × 10
6 MDA-
MB-231 cells by subcutaneous injection in one hind
flank. Tumor volume was monitored every other day by
using the equation (L*P
2)/2, where L and P denote the
longest diameter and the diameter perpendicular to the
longest diameter, respectively. Once the tumors reached
a volume greater than 120 mm
3 (approximately 33 days
after tumor cell implantation), mice were randomized
into groups of three and administered 20 μlo ft h e
HBSS vehicle or 0.5 mg NRC-03 or NRC-07 in 20 μlo f
HBSS by intratumoral injection, beginning on day 1 and
repeated on days 3 and 5. Tumor-bearing mice were
killed 1 week after the last injection. Tumors were
excised, photographed, sectioned, and stained with
hematoxylin and eosin. Stained tumor sections were
visualized under brightfield microscopy (×400 magnifica-
tion). The experiment was conducted three times.
Statistical analysis
A l ld a t aw e r ea n a l y z e db yu s i n gt h eu n p a i r e dS t u d e n tt
test, or one-way analysis of variance with the Bonferroni
multiple comparisons test, as appropriate.
Results
NRC-03 and NRC-07 kill breast cancer cells and enhance
the efficacy of chemotherapeutic drugs
MTT assays showed that NRC-03 and NRC-07 killed
T47-D, MDA-MB-231, MCF7, SKBR3, and MDA-MB-
468 breast cancer cells, as well as 4T1 mouse mammary
carcinoma cells to a similar extent and in a dose-depen-
dent manner (Figure 1a, b). SKBR3, MDA-MB-468, and
4T1 cells were most susceptible to NRC-03 (75% ± 3%,
86% ± 7%, and 94% ± 1% cytotoxicity, respectively, at 50
μM) and NRC-07 (87% ± 2%, 88% ± 10%, and 94% ±
1% cytotoxicity, respectively, at 50 μM). In contrast, T-
47D, MDA-MB-231, and MCF7 cells required 2.5- to
10-fold more NRC-03 and NRC-07 to cause significant
cytotoxicity. Nevertheless, MDA-MB-231 cells were cho-
sen as the representative cell line for the remainder of
this investigation because these breast cancer cells were
susceptible to killing by NRC-03 and NRC-07 and could
be grown as xenografts in immune-deficient NOD SCID
m i c e .I ti si m p o r t a n tt on o t et h a tN R C - 1 3 ,an o n c y t o -
toxic CAP that was used as a control peptide, did not
substantially affect the viability of breast cancer cells or
mouse mammary carcinoma cells (Figure 1c).
NRC-03-induced cytotoxicity for MDA-MB-231 cells
w a sr e d u c e di nt h ep r e s e n c eo fi n c r e a s i n g
concentrations of FBS (Additional file 1a), suggesting
neutralization by anionic serum components and/or sus-
ceptibility of the peptide to degradation by proteases.
NRC-07-induced cytotoxicity was also diminished by
FBS. Similar results were obtained with other breast
cancer cell lines (data not shown). Furthermore, mass
spectroscopic analysis of trypsin-treated NRC-03 and
NRC-07 revealed that both CAPs were extremely sensi-
tive to trypsin-mediated degradation (Additional file 1b).
An acid phosphatase cell-viability assay was used to
determine whether NRC-03 and NRC-07 were able to
kill drug-resistant breast cancer cells because drug-efflux
pumps interfere with the MTT assay [27]. MCF7-TX400
cells are resistant to paclitaxel and express 2.6-fold
more P-glycoprotein than do parental cells (data not
shown). Figure 1d shows that MCF7 and MCF7-TX400
cells were equally susceptible to 50 μM NRC-03 or
NRC-07. As expected, neither MCF7 nor MCF7-TX400
cells were killed by the control peptide NRC-13.
To determine whether NRC-03 and/or NRC-07 can
sensitize breast cancer cells to chemotherapeutic drugs,
a sublethal concentration (10 μM) of NRC-03 or NRC-
07 was added to MDA-MB-231 cells 20 minutes before
their exposure to increasing concentrations of cisplatin
(0 to 16 μg/ml). NRC-03 pretreatment reduced the EC50
of cisplatin by 5.5-fold after 72 and 96 hours, whereas
NRC-07 reduced the EC50 of cisplatin by only 1.6- and
1.7-fold after 72 and 96 hours, respectively (Figure 2).
Although not shown here, NRC-03 also enhanced killing
of MDA-MB-231 cells by docetaxel. NRC-03 is therefore
more effective than NRC-07 as a chemosensitizing
agent.
Certain CAPs are selectively cytotoxic for cancer cells,
whereas other CAPs indiscriminately kill healthy and
neoplastic eukaryotic cells [9]. Neither NRC-03 nor
NRC-07 killed primary cultures of human dermal fibro-
blasts or HUVECs at the concentrations that were
strongly cytotoxic for MDA-MB-231 breast cancer cells
( T a b l e1 ) .I na d d i t i o n ,n e i t h e rN R C - 0 3n o rN R C - 0 7
exhibited hemolytic activity. However, both NRC-03 and
NRC-07 showed substantial cytotoxicity for primary cul-
tures of HMECs, albeit less than was observed with
breast cancer cells. Nevertheless, this finding suggests
that systemic treatment with NRC-03 and NRC-07 may
have adverse consequences in vivo.
NRC-03 and NRC-07 interact with negatively-charged cell-
surface structures on breast cancer cells
Preferential binding of NRC-03 and NRC-07 to breast
cancer cells was assessed with fluorescent microscopy
analysis of MDA-MB-231 cells and normal human der-
mal fibroblasts that were exposed for 10 minutes to bio-
tinylated-NRC-03 and biotinylated-NRC-07, which had
cytotoxic activity equivalent to native NRC-03 and
Hilchie et al. Breast Cancer Research 2011, 13:R102
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fold greater binding of NRC-03 and NRC-07 to MDA-
MB-231 cells, respectively, than to fibroblasts. Interest-
ingly, NRC-03 had an eightfold greater affinity for breast
cancer cells than did equivalent concentrations of NRC-
07, even though NRC-03 and NRC-07 had equivalent
cytotoxic activity (Figure 1a).
The outer-membrane leaflet of cancer cells is nega-
tively-charged because of an abundance of anionic
molecules, whereas healthy cells are neutral in charge
[9,18]. In comparison to MDA-MB-231 cells with
intact O-sialoglycoproteins, MDA-MB-231 cells that
had their O-sialoglycoproteins removed by O-sialogly-
coprotein endopeptidase were only slightly less
Figure 1 NRC-03 and NRC-07 are cytolytic for breast cancer cells, including chemoresistant variants. T-47D, MDA-MB-231, MCF7, SKBR3,
and MDA-MB-468 breast cancer cells and 4T1 mouse mammary carcinoma cells were exposed to medium alone or the indicated concentrations
of (a) NRC-03, (b) NRC-07, or (c) NRC-13. Cell viability was determined by MTT assay after 24 hours. Data shown are statistically significant by
ANOVA (p < 0.005). (d) MCF7 or paclitaxel-resistant MCF7-TX400 cells were cultured in the presence or absence of 50 μM NRC-03, NRC-07, or
NRC-13 for 24 hours. Percentage cytotoxicity relative to cells grown in medium alone was determined with acid phosphatase assay because of
the interference of drug-efflux pumps with the reduction of MTT [27]. Cytotoxicity in cultures of NRC-03-, NRC-07, or NRC-13-treated MCF7 cells
versus MCF7-TX400 cells was not statistically significant by the Student t test (p > 0.05). All data shown represent the mean of at least three
independent experiments ± SEM.
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(Figure 3b), suggesting little if any role for O-sialogly-
coproteins as major ligands for these CAPs. Because
heparan sulfate and chondroitin sulfate proteoglycans
are anionic molecules that are often overexpressed on
neoplastic cells [11,30], we compared the cytotoxic
activity of NRC-03 and NRC-07 against native L cells
with L cells that lack heparan sulfate proteoglycan
(gro2C cells), and L cells that lack both heparan and
chondroitin sulfate proteoglycans (sog9 cells). Gro2C
and sog9 cells were less susceptible than native L cells
to killing by NRC-03 and NRC-07 (Figure 3c). Sog9
cells showed the most resistance to peptide-mediated
cytotoxicity, suggesting that both heparan sulfate and
chondroitin sulfate proteoglycans interact with NRC-
03 and NRC-07. A solid-phase binding assay confirmed
that both NRC-03 and NRC-07 were able to bind
immobilized heparan sulfate and chondroitin sulfate
proteoglycans (Figure 3d).
NRC-03 and NRC-07 cause breast cancer cell-membrane
damage
CAPs kill cancer cells by causing significant and irrepar-
able membrane damage and/or by inducing apoptosis [9].
Scanning electron microscopy was used to determine the
effect of NRC-03 and NRC-07 on the membrane integrity
of peptide-sensitive MDA-MB-231 breast cancer cells
and peptide-resistant fibroblasts. Figure 4a shows that
MDA-MB-231 cells exhibited substantial membrane
damage after exposure to 50 μM NRC-03 or NRC-07.
Peptide-treated breast cancer cells had fewer microvilli,
and those that remained were shrivelled in appearance.
Numerous pores of various sizes were evident in nearly
all peptide-treated breast cancer cells, which were swol-
len or had completely collapsed. These peptide-induced
changes in morphology are consistent with a cytolytic
mechanism of action. Normal fibroblasts remained intact
after exposure to 50 μM NRC-03 or NRC-07 (Figure 4b),
although the number of microvilli appeared to increase.
Consistent with a cytolytic effect of NRC-03 and NRC-07
on breast cancer cells, LDH was released in a time-
dependent fashion by peptide-treated MDA-MB-231
cells, peaking after 4 hours of exposure (Figure 4c).
Breast cancer cell-membrane disruption after NRC-03
and NRC-07 treatment was confirmed by propidium
iodide uptake by MDA-MB-231 cells after 10-minute
exposure to peptide (data not shown). Evidence of exten-
sive CAP-mediated damage to the cell-membrane of
breast cancer cells suggested that NRC-03 and/or NRC-
07 might be able to enter the damaged cells. Fluorescence
confocal microscopy revealed that biotinylated-NRC-03
and biotinylated NRC-07 rapidly entered the cytoplasm
of peptide-treated MDA-MB-231 cells and appeared to
localize to the nucleus (Figure 5a, b).
NRC-03 and NRC-07 cause mitochondrial membrane
damage and ROS production in breast cancer cells
Because mitochondria carry a negative charge [31],
NRC-03 and NRC-07 that enter breast cancer cells
Figure 2 NRC-03 and NRC-07 enhance cisplatin-mediated
cytotoxicity. MDA-MB-231 cells were cultured in increasing
concentrations of cisplatin in the absence or presence of 10 μM
NRC-03 or NRC-07. Cell viability, which was used to determine the
EC50 of cisplatin, was determined with MTT assay after 72 and 96
hours. The EC50 of NRC-03 and NRC-07 for MDA-MB-231 cells was
determined to be 18.7 ± 2.9 and 18.5 ± 0.9, respectively, across
multiple experiments. Data are statistically significant by the
Bonferroni multiple comparisons test in comparison with cisplatin-
treated cells; *p < 0.05. All data shown are the mean of at least
three independent experiments ± SEM.
Table 1 Cytotoxic activity of NRC-03 and NRC-07 against normal human cells in comparison to breast cancer cells
% Cytotoxicity
a % Hemolysis
b
Treatment HMECs Fibroblasts HUVECs MDA-MB-231 Erythrocytes
25 μM NRC-03 17 ± 5 0 ± 2 3 ± 3 46 ± 6 2 ± 1
50 μM NRC-03 46 ± 3 2 ± 1 19 ± 2 74 ± 4 3 ± 2
25 μM NRC-07 20 ± 4 1 ± 1 7 ± 1 29 ± 8 1 ± 1
50 μM NRC-07 47 ± 9 0 ± 3 17 ± 8 62 ± 5 1 ± 1
a, bMean cytotoxic and hemolytic activity ± SEM (n = 3) of NRC-03 or NRC-07 against cultures of normal primary human cells and MDA-MB-231 breast cancer
cells, as well as erythrocytes, was determined as described in the Methods section after 24 hours (HMECs, fibroblasts, HUVECs, and erythrocytes) and 8 hours
(MDA-MB-231) of exposure to the peptide.
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showed that mitochondrial membrane integrity was lost
after NRC-03 or NRC-07 treatment of MDA-MB-231
cells (Figure 6a). ROS generation was also detected by
DHE staining within 30 minutes of MDA-MB-231
exposure to NRC-03 and NRC-07 (Figure 6b). Release
of cytochrome c by isolated mitochondria that were
treated with NRC-03 or NRC-07 (Figure 6c) confirmed
mitochondrial membrane permeabilization by these pep-
tides. Moreover, fluorescence confocal microscopy
Figure 3 NRC-03 and NRC-07 bind to anionic structures on breast cancer cells. (a) MDA-MB-231 breast cancer cells or normal dermal
fibroblasts were cultured in the absence or presence of 50 μM biotinylated-NRC-03 or -NRC-07 for 10 minutes, stained with Texas Red-
streptavidin, and visualized by fluorescence microscopy. Peptide binding was quantified by using NIS-Elements software. Statistical significance
was determined with the Bonferroni multiple comparisons test; *p < 0.05 relative to NRC-03- and NRC-07-treated MDA-MB-231 cells, and †p <
0.05 relative to NRC-03-treated MDA-MB-231 cells. (b) MDA-MB-231 cells were incubated in the absence or presence of O-sialoglycoprotein
endopeptidease (OSGE) for 30 minutes and then cultured in the absence or presence of 50 μM NRC-03 or NRC-07. Cell viability was determined
with the MTT assay after 24 hours. Statistical significance was determined with the Bonferroni multiple comparisons test; *p < 0.05 relative to
vehicle-treated cells. (c) Wild-type L cells, gro2C cells (heparan sulfate proteoglycan-deficient L cells), or sog9 cells (heparan sulfate proteoglycan-
and chondroitin sulfate proteoglycan-deficient L cells) were cultured in the absence or presence of the indicated concentrations of NRC-03 and
NRC-07. Cell viability was determined with the MTT assay after 24 hours. Statistical significance was determined with the Bonferroni multiple
comparisons test; *p < 0.05 relative to L cells; †p < 0.05 relative to gro2C cells. (d) Biotinylated-NRC-03 and biotinylated-NRC-07 binding to
heparan sulfate (HeS) and chondroitin sulfate (CS) proteoglycans was determined by using the solid-phase heparan sulfate- and chondroitin
sulfate-binding assays. Data shown are significant by the Bonferroni multiple comparisons test; *p < 0.05 in comparison with the medium
control. All data shown are the mean of three independent experiments ± SEM.
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Page 9 of 16Figure 4 NRC-03 and NRC-07 damage the cell membrane of breast cancer cells but not fibroblasts. (a) MDA-MB-231 breast cancer cells
or (b) normal dermal fibroblasts were cultured in the absence or presence of 50 μM NRC-03 or NRC-07 for 30 minutes. Membrane damage was
visualized with scanning electron microscopy. Data shown are from a representative experiment (n = 2). (c) MDA-MB-231 cells were cultured in
the absence or presence of the indicated concentrations of NRC-03 and NRC-07. Cytotoxicity was measured with the LDH-release assay after 10
minutes, 30 minutes, and 1, 4, and 8 hours. Data are expressed as the mean ± SEM of three independent experiments.
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NRC-07 interacted with mitochondria of MDA-MB-231
cells (Additional file 2). Release of mitochondrial cyto-
chrome c into the cytosolic compartment promotes
apoptosis via caspase-9 activation [32]. However, neither
caspase activation nor ROS production was required for
NRC-03- or NRC-07-induced cytotoxicity, because pre-
treatment of MDA-MB-231 cells with the pancaspase
inhibitor Boc-D-FMK (Figure 6d) or reduced GSH (Fig-
ure 6e) failed to protect the cells from peptide-induced
cell death. Interestingly, TUNEL staining showed DNA
fragmentation in NRC-07-treated MDA-MB-231 cells,
although DNA appeared intact in NRC-03-treated
MDA-MB-231 cells (Additional file 3).
Because autophagy has been reported sometimes to pre-
cede mitochondria-mediated apoptosis in cancer cells
treated with a cytotoxic agent [33], we compared the effect
of NRC-03 and NRC-07 on wild-type and autophagy-
related gene 5 (ATG5)-deficient mouse embryo fibroblasts
that are refractory to autophagy-like cell death [26]. How-
ever, no difference in sensitivity to killing by the CAPs was
noted (Additional file 4), suggesting that NRC-03 and
NRC-07 do not cause autophagy-like cell death.
NRC-03 and NRC-07 inhibit breast cancer xenograft
growth
Finally, we tested the in vivo activity of NRC-03 and
NRC-07 in immune-deficient NOD SCID mice
implanted with MDA-MB-231 breast cancer cells,
which form subcutaneous tumors. Xenografted tumor-
bearing mice received intratumoral injections of HBSS
alone or 0.5 mg NRC-03 or NRC-07 on days 1, 3, and
5 once tumors reached a volume of at least 120 mm
3.
Tumor volume was then monitored over the next 12
days. As shown in Figure 7a, peptide-treated tumors
failed to grow beyond their initial size after the start of
treatment and, in the case of NRC-03-treated tumors,
were significantly smaller (p <0 . 0 5 )t h a nc o n t r o l
tumors at day 12. NRC-07-treated tumors showed a
similar trend, but the difference did not reach statisti-
cal significance. In contrast, tumors that were injected
with the NRC-13 control peptide did not exhibit
reduced growth (Additional file 5). NRC-03- and NRC-
07-treated tumors also appeared to be smaller both
before and after excision (Figure 7b, c). Hematoxylin-
and-eosin staining showed that peptide-treated tumors
contained a larger necrotic area (outlined by dashed
lines) than did HBSS-treated tumors (Figure 7d),
which is consistent with NRC-03- and NRC-07-
mediated lysis of tumor cells. Intratumoral administra-
tion of the CAPs did not have any discernable adverse
effects on the mice. Necropsies conducted on control
and peptide-treated animals did not reveal any marked
differences between treatment groups, nor were there
significant differences in weight.
Discussion
Chemotherapeutic drugs that are currently used in can-
cer treatment are limited by their nonspecific toxicity,
Figure 5 NRC-03 and NRC-07 enter breast cancer cells and
localize to the nucleus. MDA-MB-231 breast cancer cells were
cultured in the presence or absence of 50 μM biotinylated-NRC-03,
or -NRC-07 for 30 seconds. (a) The actin cytoskeleton and
biotinylated-peptides were visualized with confocal microscopy
(×1,000) by using Alexa-Fluor 488-phalloidin and Texas Red-
conjugated streptavidin, respectively. (b) The nucleus and
biotinylated-peptides were visualized with confocal microscopy
(×1,000) by using TO-PRO-3 iodide and Texas Red-conjugated
streptavidin, respectively. Images shown are from a representative
experiment (n = 3).
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cells, and potential to cause secondary malignancies
[3,4,6]. These drawbacks have stimulated the search for
novel anticancer agents that selectively kill cancer cells,
including drug-resistant variants, regardless of their rate
of growth. In this study, we showed for the first time
that pleurocidin-family CAPs NRC-03 and NRC-07 are
cytotoxic for multiple breast cancer cell lines, including
SKBR3 cells that contain a 100% ALDEFLUOR-positive
breast cancer stem cell population [34]. In addition,
only 4-hour exposure to NRC-03 or NRC-07 was
needed to reduce significantly the viability of paclitaxel-
resistant MCF7-TX400 cells, indicating that these CAPs
are able to kill drug-resistant breast cancer cells. NRC-
03 and NRC-07 also killed cisplatin-resistant ovarian
cancer cells (Hilchie and Hoskin, unpublished data),
Figure 6 NRC-03- and NRC-07-mediated cytotoxicity is associated with mitochondrial membrane damage and ROS generation. MDA-
MB-231 breast cancer cells were cultured in the absence or presence of NRC-03 or NRC-07 for 30 minutes. (a) DiOC6 or (b) DHE was added to
cells to detect a loss of mitochondrial transmembrane potential and ROS generation, respectively. Solid peak, medium alone. Open peak, 50 μM
NRC-03 or NRC-07 treatment. (c) Mitochondria were isolated from MDA-MB-231 cells and treated with NRC-03 or NRC-07, as described earlier, for
10 minutes. Cytochrome c was detected in the supernatant and mitochondria fractions with Western blot analysis. Mitochondrial Hsp70 was
detected to confirm equal protein loading. Data shown are from a representative experiment (n = 3). MDA-MB-231 cells were pretreated with
(d) 40 μM Boc-D-FMK or (e) 5m M GSH before exposure to 50 μM NRC-03 or NRC-07. Percentage cytotoxicity was assessed with MTT and acid
phosphatase viability assays, respectively. Data shown are the mean ± SEM of three independent experiments and are not statistically significant
(p > 0.05) in comparison with controls with the Bonferroni multiple comparisons test.
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that develop chemoresistance by mechanisms other than
increased expression of P-glycoprotein.
NRC-03 and NRC-07 did not substantially harm
HUVECs or human fibroblasts at concentrations that
were strongly cytolytic for breast cancer cells; however,
HMECs were susceptible to killing by both peptides.
N e v e r t h e l e s s ,t h en o n s p e c i f i ct o x i c i t yo fs y s t e m i cN R C -
03 and NRC-07 might still be less than that of tradi-
tional chemotherapeutic agents. Moreover, the
Figure 7 NRC-03 and NRC-07 halt the growth of breast cancer xenografts in mice. MDA-MB-231 breast cancer cells were implanted in the
right hind flank of NOD SCID mice. Once tumors reached a volume at least 120 mm
3, they were injected with the HBSS alone or with 0.5 mg
NRC-03 or NRC-07 (in HBSS) on days 1, 3, and 5. (a) Tumor volume was determined on days 1, 3, 5, 7, 9, 11, and 12 after the start of peptide
treatment. Data shown are the mean tumor volume ± SEM from three independent experiments (three mice per group conducted three times
for a total of nine mice per treatment). Statistical significance was determined with the Bonferroni multiple comparisons test; *p < 0.05
compared with HBSS-treated animals. (b) On day 12, mice were killed and photographed, and (c) the tumors were excised and photographed
(d). Tumor sections were stained with hematoxylin and eosin, and photographed by using bright-field microscopy (×400). Scale bars indicate
400 μm. T, viable cells; N, necrotic cells. Representative images are shown.
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reduced by the addition of cancer cell-targeting moieties
[15,16,35]. In addition, CAPs can be modified for pH-
dependent activation in the acidic tumor microenviron-
ment by replacing lysine and/or arginine residues with
histidine residues [36]. Importantly, neither NRC-03 nor
NRC-07 exhibited hemolytic activity, which is a draw-
back that reduces the therapeutic utility of some other
a-helical CAPs [23].
CAPs such as NRC-03 and NRC-07 that exhibit antic-
ancer activity are believed to target cancer cells on the
basis of charge rather than the rate of cell growth
(9,11,12), which gives CAPs a completely different
mechanism of action than that of conventional che-
motherapeutic agents. NRC-03 and NRC-07 exhibited a
56- and 98-fold greater binding capacity, respectively, to
breast cancer cells than to normal fibroblasts, even
though the doubling time of the neoplastic epithelial
cells was approximately the same as that of the untrans-
formed fibroblasts. The potent cytolytic activity of NRC-
03 and NRC-07 against slow-growing SKBR3 cells (~36-
hour doubling time) suggests that these peptides may be
effective against indolent tumors. Peptide binding to
anionic heparan sulfate proteoglycans and chondroitin
sulfate proteoglycans was involved in NRC-03- and
NRC-07-mediated cytotoxicity; however, none of these
molecules was exclusively necessary for target-cell death,
suggesting that NRC-03 and NRC-07 interact with addi-
tional negatively-charged molecules on the surface of
susceptible cells. In this regard, increased density of
negatively-charged phosphatidylserine on the surface of
cancer cells has been suggested to serve as a target for
CAPs [37]. Because many different negatively-charged
molecules contribute to the overall anionic charge of
cancer cells that renders them susceptible to CAP-
mediated killing, it is unlikely that breast cancer and
other malignant cells will be able easily to acquire resis-
tance to cytotoxic CAPs such as NRC-03 and NRC-07.
Electrostatic interactions between breast cancer cells
and NRC-03 or NRC-07 resulted in severe damage to
the cell membrane, as demonstrated with scanning elec-
tron microscopy, propidium iodide uptake, and the
release of cellular LDH. Integration of bulky hydropho-
bic amino acids into the hydrophobic core of the target
cell membrane and adoption of a stable amphipathic
structure is believed to lead to pore formation by CAPs
[9]. Interestingly, percentage cytotoxicity in LDH-release
assays typically exceeded cytotoxicity measured by MTT
assays, suggesting that the MTT assay underestimated
the killing of breast cancer cells by NRC-03 and NRC-
07. In addition, treatment with NRC-03 and NRC-07
caused mitochondrial transmembrane potential to be
lost in breast cancer cells, as well as inducing ROS pro-
duction, possibly as a result of the CAPs targeting and
damaging mitochondria, because fluorescence confocal
microscopy showed colocalization of peptides and mito-
chondria. Moreover, NRC-03 and NRC-07 were able to
permeabilize preparations of isolated mitochondria.
However, apoptosis and ROS generation associated with
mitochondrial permeabilization was not required for
NRC-03- and NRC-07-mediated cytotoxicity because the
addition of a pancaspase inhibitor or reduced GSH
failed to protect breast cancer cells from killing by the
peptides. Nevertheless, NRC-07 was able to cause DNA
fragmentation in breast cancer cells, as indicated by
TUNEL staining. Interestingly, both NRC-03 and NRC-
07 appeared to localize rapidly to the nucleus of pep-
tide-treated breast cancer cells, possibly because of pep-
tide interactions with anionic nucleic acids. We
conclude that NRC-03 and NRC-07 directly kill breast
cancer cells by a membranolytic mechanism, although
w ec a n n o tr u l eo u tt h ep o s s i b i l i t yt h a tN R C - 0 3 -a n d / o r
NRC-07-induced pore formation in mitochondria may
contribute to cytotoxicity.
It is also conceivable that prolonged exposure to lower
concentrations of NRC-03 and/or NRC-07 may cause
transient cell-membrane damage and induce cell death
by mitochondrial-dependent apoptosis or an inhibition
of macromolecular synthesis. This dual effect of pleuro-
cidin has been demonstrated in bacteria [38]; however,
the impact of prolonged exposure to low concentrations
of NRC-03 and NRC-07 on breast cancer cell viability
has not yet been investigated.
Sublethal concentrations of NRC-03, and, to a lesser
extent, NRC-07, significantly reduced the EC50 of cispla-
tin, leading us to conclude that NRC-03 and NRC-07
possess chemosensitizing properties. A membranolytic
mechanism of action likely accounts for the observed
ability of NRC-03 and NRC-07 to enhance the killing of
breast cancer cells by cisplatin. In addition, nuclear loca-
lization of NRC-03 and NRC-07 is predicted to disrupt
the nuclear membrane and allow easier access of cispla-
tin and other DNA-crosslinking agents to the nucleus.
However, it is not yet known whether sublethal doses of
NRC-03 and/or NRC-07 similarly enhance in vivo cyto-
toxicity mediated by chemotherapeutic drugs.
Unlike control breast cancer xenografts in NOD SCID
mice, flank tumors that received intratumoral injections
of NRC-03 or NRC-07 did not increase in size once
peptide treatment was started, whereas tumors that
were injected with a noncytotoxic control peptide grew
at the same rate as HBSS-injected tumors. In addition,
histologic analysis revealed that the necrotic core of
peptide-treated tumors was larger than that of control
tumors, which is consistent with the in vitro cytolytic
activity of NRC-03 and NRC-07. Importantly, intratu-
moral delivery of NRC-03 and NRC-07 to mice did not
have any noticeable adverse side-effects, indicating that
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intratumoral injection. Interestingly, Berge and collea-
gues [19] recently demonstrated that intratumoral injec-
tion of another lytic peptide stimulated a protective
antitumor immune response in immune-competent
mice as a result of peptide-mediated lysis of tumor cells
providing an immunostimulatory “danger signal” to T
cells. The cytolytic mechanism of action of NRC-03 and
NRC-07 suggests that intratumoral administration of
these peptides may also stimulate an antitumor immune
response.
Conclusions
Conventional chemotherapeutic drugs are limited by
their lack of specificity for cancer cells and their inability
to kill multidrug-resistant and slow-growing cancer cells.
We have shown for the first time that the pleurocidin-
family CAPs NRC-03 and NRC-07 are cytotoxic for
multiple breast cancer cell lines, including MCF7-TX400
cells that overexpress P-glycoprotein, and slow-growing
SKBR3 cells that contain a 100% ALDEFLUOR-positive
breast cancer stem cell population. We established that
NRC-03- and NRC-07-mediated cell death is initiated
by peptide binding to negatively-charged molecules on
the surface of breast cancer cells. NRC-03 also substan-
tially reduces the EC50 of cisplatin, suggesting the possi-
ble use of NRC-03 as a chemosensitizing agent.
Importantly, both NRC-03 and NRC-07 killed breast
cancer cells grown in NOD SCID mice. These findings
indicate that NRC-03 and NRC-07 have several advan-
tages over conventional chemotherapeutic drugs and
warrant further investigation as possible novel antican-
cer agents.
Additional material
Additional file 1: NRC-03 and NRC-07 are susceptible to
degradation by proteases. (a) MDA-MB-231 cells cultured in the
presence of 0.5, 2.5, and 5% FBS were exposed to 50 μM NRC-03 or NRC-
07. Cell viability was determined with MTT assay after 24 hour. Data
shown are statistically significant by ANOVA (p < 0.05) and represent the
mean of three independent experiments ± SEM. (b) The 50 μg of NRC-
03 or NRC-07 was combined with 1 μg trypsin and incubated overnight
at 37°C. Intact and/or fragmented peptides were detected with MALDI-
TOF mass spectrometry. Data shown are from one experiment.
Additional file 2: NRC-03 and NRC-07 interact with mitochondria in
breast cancer cells. MDA-MB-231 breast cancer cells were cultured in
the presence or absence of 50 μM biotinylated-NRC-03 or biotinylated-
NRC-07 for 30 seconds. Biotinylated peptides and mitochondria were
visualized with confocal microscopy (×1,000) by using Texas Red-
conjugated streptavidin and anti-mitochondrial Hsp70 mAb, respectively.
Arrows point to sites of colocalization. Images shown are from a
representative experiment (n = 3).
Additional file 3: NRC-07, but not NRC-03, causes DNA
fragmentation in breast cancer cells. MDA-MB-231 breast cancer cells
were cultured in the presence or absence of 50 μM NRC-03 or NRC-07
for 30 minutes. DNA fragmentation was detected with TUNEL staining
that was visualized with fluorescence microscopy. Data shown are from a
representative experiment (n = 3).
Additional file 4: NRC-03 and NRC-07 do not cause autophagy-like
cell death. ATG5
+/+ or ATG5
-/- mouse embryo fibroblasts (MEFs) were
cultured in the presence or absence of 50 μM NRC-03 or NRC-07. Cell
viability was determined with MTT assay after 24 hours. No statistically
significant difference (p > 0.05) was found between peptide-mediated
killing of ATG5
+/+ or ATG5
-/- mouse embryo fibroblasts, as determined
with the Student t test. Data shown are the mean of at least three
independent experiments ± SEM.
Additional file 5: The noncytotoxic control peptide NRC-13 does
not have antitumor activity. MDA-MB-231 breast cancer cells were
implanted in the hind flanks of NOD SCID mice. Once tumors reached a
volume at least 120 mm
3, they were injected with HBSS alone or with
0.5 mg NRC-03 or NRC-13 (in HBSS) on days 1, 3, and 5. Tumor volumes
were determined on days 1, 3, 5, 7, 9, 11, and 12 after the start of
peptide treatment. Data shown are the mean of five animals ± SD.
Statistical significance was determined with the Bonferroni multiple
comparisons test; *p < 0.05 compared with HBSS-treated animals.
Abbreviations
CAP: Cationic antimicrobial peptide; CFU: colony-forming units; DHE:
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